Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study

Br J Dermatol. 2024 Apr 17;190(5):769-771. doi: 10.1093/bjd/ljae042.
No abstract available

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal, Humanized*
  • Cohort Studies
  • Denmark
  • Hidradenitis Suppurativa*
  • Humans
  • Infliximab
  • Ustekinumab*

Substances

  • Adalimumab
  • Ustekinumab
  • Infliximab
  • secukinumab
  • Antibodies, Monoclonal, Humanized